Release Date: July 31, 2025
Expiration Date: July 31, 2026
Activity Overview
Triple-negative breast cancer (TNBC) remains a cancer of significant unmet need, with limited treatment options beyond systemic chemotherapy. Recently, TROP2 has emerged as a target of interest, and antibody-drug conjugates (ADCs) targeting TROP2 can provide substantial clinical benefit to patients with TNBC. However, physicians who incorporate treatments that exploit TROP2 must navigate practical challenges of treating the disease and managing adverse events.
In this dynamic tumor board program, expert faculty address these issues and guide structured discussions on the latest evidence surrounding the role of TROP2-targeted therapies and ADC-sequencing strategies for the treatment of TNBC. Through education, clinicians will be better equipped to provide quality care and optimize outcomes for their patients with TNBC. This program took place in conjunction with the 24th Annual International Congress on the Future of Breast Cancer®—East conference.
This educational activity is an archive of the live virtual symposium held on July 11, 2025.
Target Audience
This educational activity is directed toward physicians, nurses, nurse practitioners, physician assistants, and other health care providers involved in the treatment and management of TNBC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate efficacy and safety data from clinical trials evaluating TROP2–targeted antibody-drug conjugates (ADCs) for triple-negative breast cancer (TNBC)
- Integrate TROP2-targeted ADCs into individualized treatment plans for patients with TNBC
- Discuss disparities in care among diverse populations of patients with TNBC, including potential root causes and regional differences in attitudes and practice patterns
Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Director, Breast Cancer Research Program
Texas Oncology
US Oncology
Dallas, TX
Disclosures: Consultant: AbbVie, Agendia, Amgen, Aptitude Health, AstraZeneca, BioNTech, Byondis, Carrick Therapeutics, Daiichi Sankyo, DAVA Oncology, Eisai, Eli Lilly and Company, Fishawack Health, G1 Therapeutics, Genentech, Genzyme, Gilead Sciences, GSK, Loxo Oncology, Merck, Novartis, Ontada, Pfizer, Pierre Fabre, Puma Biotechnology, Roche, Samsung Bioepis, Sanofi, Seagen, Stemline Therapeutics, Taiho Oncology, Verily
Matthew P. Goetz, MD
Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, MD
Professor of Oncology and Pharmacology
Enterprise Deputy Director, Translational Research
Mayo Clinic
Rochester, MN
Disclosures: Consulting Fees: AstraZeneca, AstraZeneca Pharmaceuticals LP, AstraZeneca UK Ltd, BeiGene USA, Biotheranostics, Biotheryx, eChinaHealth, EcoR1, Engage Health Media, Genentech, Incyclix, Laekna, Lilly, Novartis, RNA Diagnostics, Seattle Genetics, Sermonix, Stemline Therapeutics, TerSera Therapeutics; Grant Funding: AstraZeneca, ATOSSA Therapeutics, Biotheryx, Lilly, Loxo, Pfizer, Sermonix, SimBioSys; Travel Support: Lilly
Hope S. Rugo, MD, FASCO
Director, Women’s Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology & Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA
Professor Emeritus, UCSF
Disclosures: Adviser: Ambrx, Chugai, OBI Pharma, Puma; Consultant: Ambrx, Chugai, Mylan, Napo, OBI Pharma, Puma, Sanofi; Researcher: AstraZeneca, Daiichi Sankyo, F. Hoffman-La Roche AG/Genentech, Gilead Sciences, Lilly, Merck & Co, Novartis Pharmaceuticals Corporation, Pfizer, Stemline Therapeutics.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here